Chemotherapy-Induced Neutropenia Prevention: Implications of New Clinical Data and Guidelines Faculty: Jeffrey C. Crawford, MD | David C. Dale, MD | Gary H. Lyman, MD, MPH, FRCP (Edin) | Christopher R. Friese, RN, PhD, AOCN® CME / CE credit hour: 1.0
Chemotherapy-induced neutropenia has very serious and important clinical consequences in terms of medical care, quality of life, and economic factors for cancer treatment. Chemotherapy patients who develop neutropenia are at risk of developing febrile neutropenia, which is a medical emergency that requires immediate medical management. Febrile neutropenia has historically been treated through the use of prophylactic antibiotics, but their usefulness continues to be controversial and the incidence of febrile neutropenia continues to be high. The use of hematopoetic colony stimulating factors (CSFs) has improved the outcomes for patients who experience febrile neutropenia.
The Conundrum of Rash in Management of EGFR Inhibitors(Accreditation Expired) Faculty: Roy S. Herbst, MD, PhD | Mario Lacouture, MD | Roman Perez-Soler, MD | Sandy Kurtin, RN, MS, AOCN®, NP CME / CE credit hour: 1.0 New therapies targeting the epidermal growth factor receptor (EGFR) have been used in the treatment of a variety of cancers. Although generally well tolerated, EGFR inhibitors are associated with the development of dermatologic reactions (e.g., papulopustular rash, xerosis, pruritus, periungual inflammation, and alopecia) in most patients. At present, little is known about the etiology of these reactions, and no evidence-based management guidelines have been set forth in the dermatologic literature.
Patient Reviews in Myeloma E-Learning (Accreditation Expired) Faculty: Sundar Jagannath, MD | Robert Z. Orlowski, MD, PhD | Paul G. Richardson, MD CME credit hours: earn up to 8.0 credit hours While there are standard treatment paradigms for patients with multiple myeloma, the majority of patients eventually relapse. A number of new agents, including the immunomodulatory agents thalidomide and lenalidomide and the proteasome inhibitor bortezomib, have demonstrated impressive response rates in combination with established regimens and offer new hope for patients. Log on to review an interesting case study to earn .5 credits. Additionally, you have the opportunity to submit your own case studies for additional CME credits and the opportunity to be selected as a speaker for 1 of 2 upcoming Web conferences.
All information content within shall be considered confidential property of ArcMesa Educators, LLC
and should not be disclosed or redistributed to third parties without express permission.
Chemotherapy-Induced Neutropenia: Impact, Risks & Prevention
